Cervical Cancer Staging: Sensitivity and Specificity

Introduction: For screening and initial diagnosis of Cervical Cancer, see that page.

The FIGO staging system is clinical and is as follows, in brief:

Stage I - confined to uterus

Stage II - invades beyond uterus but not to pelvic wall or to the lower third of vagina

Stage III - Tumor extends to the pelvic wall, and/or involves the lower third of the vagina, and/or causes hydronephrosis or nonfunctioning kidney

Stage IV - extension beyond the true pelvis or has involved (biopsy proven) the bladder mucosa or rectal mucosa

The sensitivity and specificity of findings for Cervical Cancer Staging are listed below. See the left navigation bar to change the display.

Specific Findings

29%

99%

for stage >=IIB

FIGO staging allows/involves:

Palpation and inspection of the primary tumor

Palpation of groin and supraclavicular lymph nodes

Colposcopy

Endocervical curettage

Conization

Hysteroscopy

Cystoscopy

Proctoscopy

Intravenous pyelogram (IVP)

Radiographic examination of the lungs and skeleton

Study: J Clin Oncol. 2005 Dec 20;23(36):9329-37. PMID 16361632

Poorly Diagnostic Findings

42%

82%

for Stage >= IIB

Study: J Clin Oncol. 2005 Dec 20;23(36):9329-37. PMID 16361632

53%

74%

for stage >= IIB

Study: J Clin Oncol. 2005 Dec 20;23(36):9329-37. PMID 16361632